Sign in
Taking people in United StatesPhase 1

AO-252 pill for advanced solid tumors, including those spread to the brain

Tests AO-252 for safety and dose in adults with advanced solid tumors.

Key facts

Who runs it
A2A Pharmaceuticals Inc.
Where
Charleston, Dallas, Detroit, Fairfax, Houston, and Oklahoma City, United StatesSee the 6 sites
Trial code
Registry title
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Status
Recruiting
Phase
Phase 1
People taking part
86 people, planned
Started
2 Nov 2023
Expected to end
27 Jan 2028
Type of study
Interventional, 2 groups
Treatments tested
  • AO-252
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors, with or without spread to the brain, to test the oral drug AO-252. Men with prostate cancer that no longer responds to hormone therapy can also join.

Age
18 years and older
Sex
All sexes
Disease stage
Solid tumor that has spread or grown locally and cannot be removed by surgery, with or without brain metastases. Must have measurable disease per RECIST v1.1. ECOG performance status of ≤ 1 (fully active or only mild limits). Life expectancy of ≥ 3 months. For prostate cancer: mCRPC adenocarcinoma, without neuroendocrine features or mixed histology. For brain spread: at least one untreated brain lesion ≥0.5 cm (0.2 in) and <3.0 cm (1.2 in), not needing immediate brain treatment.
Earlier treatment
Cancer must have come back or not responded after at least 1 line of whole-body therapy for metastatic disease (not counting melanoma). Prostate cancer: surgical or medical castration, and progression on at least 1 prior AR-targeted drug (abiraterone acetate, apalutamide, enzalutamide, darolutamide) and/or at least 1 prior chemotherapy (e.g., docetaxel). No anticancer therapy within 3 weeks or 5 half-lives. Prior SRS radiosurgery is allowed if it does not overlap the current target areas.
Biomarker or test result
TP53 mutation or loss in the tumor (not required for prostate cancer). Prostate cancer: PSA of ≥ 2 ng/mL and testosterone less than 50 ng/dL.

Main reasons for not taking part

  • Brain metastases causing symptoms that need treatment, or cancer spread to the brain lining (leptomeningeal disease)
  • Another cancer within 3 years, apart from some treated skin cancers or in-situ carcinoma
  • Pregnant or breastfeeding
  • Unable to take pills by mouth because of bowel or stomach disease
  • HIV without effective treatment and undetectable virus, or active hepatitis B or untreated hepatitis C

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Adults ≥ 18 years of age
  • Patient has histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors with TP53 mutation/loss and with/without brain metastasis. Patients must have relapsed/be refractory to at least 1 line of systemic therapy in the metastatic setting (excluding melanoma)
  • Prostate cancer:; mCRPC with histologic confirmation of adenocarcinoma. mCRPC with neuroendocrine features or mixed histology are excluded; Patients will be enrolled irrespective of the TP53 status; Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL; Is surgically or medically castrated, with testosterone levels of less than 50 ng/dL; Patients who progressed on at least 1 prior novel androgen receptor AR-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), and or at least 1 prior systemic chemotherapy (e.g., docetaxel)
  • Solid tumors with brain metastasis:; Histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors excluding melanoma with TP53 mutation/loss and tumor must have relapsed/be refractory to at least 1 line of systemic therapy. Untreated brain metastases not requiring immediate local CNS therapy; Previously treated brain metastases with progression of previous lesions or new lesions, but not requiring immediate local CNS therapy; At least one measurable untreated brain lesion ≥0.5 cm and <3.0 cm in the longest axis; Prior SRS radiosurgery (must be completed within 7 days of study treatment initiation) is allowed as long as the previous treatment volume does not overlap with the current targets
  • Measurable disease per RECIST v1.1 criteria. For mCRPC patients, tumor response will be evaluated using RECIST version 1.1 (soft tissue) and PCWG-3 criteria (bone) and efficacy endpoints will also include radiographic progression-free survival (rPFS), PSA50 response and PSA progression
  • Adequate bone marrow reserve, cardiac, liver, and renal function:; Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL; Bilirubin ≤ 1.5 × upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 × ULN; Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present); INR ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants; Creatinine clearance ≥ 60 mL/min (by Cockroft Gault formula)
  • Female patients of child-bearing potential must have a negative serum pregnancy test and use at least 1 form of acceptable birth control method listed below as approved by the Investigator before initiating study treatment and for 3 months after the last dose of study drug; Sterilization; Any hormonal contraceptives (non-CYP 3A4 inhibitors) associated with inhibition of ovulation; IUD (intrauterine device) or intrauterine hormone releasing system
  • Male patients must be sterilized or use a form of barrier contraception, such as condoms with spermicide, during the study and for 3 months after the last dose of study drug
  • Life expectancy of ≥ 3 months
  • Ability to provide written informed consent
  • An Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

Who cannot take part

  • Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the Investigator (e.g., uncontrolled congestive heart failure, active infection)
  • Radiation therapy to > 30% of bone marrow within 3 months before study entry
  • Patient has received systemic anticancer therapy within 3 weeks or 5 half-lives, whichever is shorter
  • Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline
  • Known HIV-infected patients unless on effective anti-retroviral therapy with an undetectable viral load within 6 months and no opportunistic infection within the past 12 months, or b. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or c. Known or suspected hepatitis C infection that has not been treated and cured unless currently on treatment with an undetectable viral load
  • Administration of strong or moderate cytochrome (CYP) 3A4 inhibitors and inducers within 14 days or 5 half-lives (whichever is shorter) prior to the administration of study drug
  • Patients with symptomatic brain metastases requiring treatment and/or leptomeningeal disease
  • Patients with a previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 3 years of study entry
  • Patients with gastrointestinal tract disease causing the inability to take oral medication (e.g., swallowing difficulties, malabsorption syndromes, extensive small bowel resection [> 100cm], gastric bypass surgery)
  • Known human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (excluding cured HBV and/or cured HCV infection)
  • Patients with clinically significant autoimmune disease, either currently present of present within 2 years, including a current requirement for systemic immunosuppressive therapy equivalent to > 10 mg/prednisone daily (local immunosuppressive therapy such as inhaled or topical corticosteroids is allowed)
  • Any of the following conditions (on-study testing is not required):
  • Patients with abnormal or clinically significant electrocardiogram (ECG) abnormality, including but not limited to a confirmed corrected QT interval using Fridericia's formula (QTcF) > 470 msec
  • Patients with uncontrolled pleural effusions, pericardial effusion, or ascites that do not resolve
  • Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception

This trial is currently available in United States.

  • Hollings Cancer Center - MUSCCharleston, United StatesContact: Recruitment CoordinatorTaking people
  • Mary Crowley Cancer ResearchDallas, United StatesContact: Angela HotchkissTaking people
  • Karmanos Cancer InstituteDetroit, United StatesContact: Ira Winer, MD (principal investigator)Taking people
  • NEXT Oncology- VirginiaFairfax, United StatesContact: Anthony YoungTaking people
  • The University of Texas M. D. Anderson Cancer CenterHouston, United StatesContact: Guoxin FengTaking people
  • Oklahoma UniveristyOklahoma City, United StatesContact: Christina CaldwellTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.

The 2 groups in the trial

  • Part 1: Dose EscalationTreatment being tested

    Participants will be assigned to dose levels.

    Treatment: AO-252

  • Part 2: Dose ExpansionTreatment being tested

    After doses are decided in Part 1, participants entering part 2 will be assigned to a dose level.

    Treatment: AO-252

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases
Plain-language title
AO-252 pill for advanced solid tumors, including those spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
17 August 2026